Galectin Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:PHPN Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
30 Dec 24	Buy€7,267	Harold Shlevin	Individual	6,500	€1.12
24 Dec 24	Buy€7,829	Kevin Freeman	Individual	10,000	€0.78
24 Dec 24	Buy€10,630	Kary Eldred	Individual	13,469	€0.79
24 Dec 24	Buy€7,858	Richard Zordani	Individual	10,000	€0.79
23 Oct 24	Buy€1,206	Kary Eldred	Individual	500	€2.41
17 Oct 24	Buy€3,169	Kevin Freeman	Individual	1,300	€2.44
16 Oct 24	Buy€24,824	Kevin Freeman	Individual	10,000	€2.48
23 Aug 24	Buy€7,192	Richard Zordani	Individual	3,500	€2.05
22 Jul 24	Buy€878	Kary Eldred	Individual	400	€2.20
20 Jun 24	Buy€5,552	Kevin Freeman	Individual	2,500	€2.22
30 Apr 24	Buy€3,292	Richard Zordani	Individual	1,000	€3.29
24 Apr 24	Buy€3,172	Joel Lewis	Individual	1,000	€3.17
23 Apr 24	Sell€71,497	10x Capital Management, LLC	Company	25,000	€2.86
22 Apr 24	Buy€6,999	Kevin Freeman	Individual	2,500	€2.80

Insider Trading Volume

Insider Buying: PHPN insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of PHPN?
Owner Type	Number of Shares	Ownership Percentage
Private Companies	75,432	0.12%
Hedge Funds	5,922,207	9.44%
Institutions	9,826,586	15.7%
Individual Insiders	12,863,239	20.5%
General Public	34,074,361	54.3%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 43.44% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
16.4%	Richard Uihlein	10,306,461	€12.5m	0.1%	no data
9.44%	10x Capital Management, LLC	5,922,207	€7.2m	0%	100.0%
3.4%	The Vanguard Group, Inc.	2,134,205	€2.6m	0.86%	no data
2.56%	BlackRock, Inc.	1,607,124	€2.0m	2.77%	no data
1.88%	Osaic Wealth, Inc. , Asset Management Arm	1,182,095	€1.4m	5.16%	no data
1.43%	Joel Lewis	899,012	€1.1m	0%	no data
1.37%	Geode Capital Management, LLC	862,542	€1.0m	2.47%	no data
1.22%	James Czirr	764,616	€928.7k	0.75%	no data
0.8%	Kary Eldred	499,634	€606.9k	2.88%	no data
0.77%	Commonwealth Equity Services, LLC	483,264	€587.0k	-0.02%	no data
0.63%	Wealthspire Advisors LLC	398,374	€483.9k	0%	no data
0.56%	Geneos Wealth Management, Inc., Asset Management Arm	352,935	€428.7k	-10.4%	0.02%
0.4%	State Street Global Advisors, Inc.	251,014	€304.9k	9.32%	no data
0.39%	Morgan Stanley, Investment Banking and Brokerage Investments	245,050	€297.6k	11.6%	no data
0.37%	Northern Trust Global Investments	234,280	€284.6k	84.5%	no data
0.33%	Atria Wealth Solutions, Inc.	207,100	€251.6k	-3.13%	no data
0.23%	Kevin Freeman	142,832	€173.5k	17.5%	no data
0.22%	Soltis Investment Advisors, LLC	140,750	€171.0k	0%	0.02%
0.18%	Cutter & Company, Inc., Asset Management Arm	115,488	€140.3k	0%	0.03%
0.18%	Cambridge Investment Research Advisors, Inc.	114,720	€139.3k	2.31%	no data
0.13%	Gilbert Omenn	82,240	€99.9k	0%	no data
0.13%	LPL Financial Corporation, Asset Management Arm	81,908	€99.5k	-6.13%	no data
0.13%	Susquehanna International Group, LLP, Asset Management Arm	81,467	€98.9k	-59.7%	no data
0.13%	Sanctuary Advisors, LLC	79,113	€96.1k	-21.4%	no data
0.12%	Cross Consulting and Services, LLC	75,432	€91.6k	-85.2%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/17 14:59
End of Day Share Price	2025/01/16 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Galectin Therapeutics Inc. is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Keay Nakae	Ascendiant Capital Markets LLC
Mayank Mamtani	B. Riley Securities, Inc.
Vernon Bernardino	Dawson James Securities